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Estradiol-17ß-D-glucuronide (E17G) activates different signaling pathways (e.g., Ca21-
dependent protein kinase C, phosphoinositide 3-kinase/protein kinase B, mitogen-
activated protein kinases [MAPKs] p38 and extracellular signal-related kinase 1/2, and
estrogen receptor alpha) that lead to acute cholestasis in rat liver with retrieval of the
canalicular transporters, bile salt export pump (Abcb11) and multidrug resistance-
associated protein 2 (Abcc2). E17G shares with nonconjugated estradiol the capacity to
activate these pathways. G-protein-coupled receptor 30 (GPR30) is a receptor implicated
in nongenomic effects of estradiol, and the aim of this study was to analyze the poten-
tial role of this receptor and its downstream effectors in E17G-induced cholestasis. In
vitro, GPR30 inhibition by G15 or its knockdown with small interfering RNA strongly
prevented E17G-induced impairment of canalicular transporter function and localiza-
tion. E17G increased cyclic adenosine monophosphate (cAMP) levels, and this increase
was blocked by G15, linking GPR30 to adenylyl cyclase (AC). Moreover, AC inhibition
totally prevented E17G insult. E17G also increased protein kinase A (PKA) activity,
which was blocked by G15 and AC inhibitors, connecting the links of the pathway,
GPR30-AC-PKA. PKA inhibition prevented E17G-induced cholestasis, whereas exchange
protein activated directly by cyclic nucleotide/MAPK kinase, another cAMP downstream
effector, was not implicated in cAMP cholestatic action. In the perfused rat liver model,
inhibition of the GPR30-AC-PKA pathway totally prevented E17G-induced alteration in
Abcb11 and Abcc2 function and localization. Conclusion: In conclusion, activation of
GPR30-AC-PKA is a key factor in the alteration of canalicular transporter function and
localization induced by E17G. Interaction of E17G with GPR30 may be the first event
in the cascade of signaling activation. (HEPATOLOGY 2013; 00:000-000)
H
epatocanalicular adenosine-triphosphate-
dependent transporters are essential for bile
secretion1 and alteration in their expression,
localization, or activity results in secretory failure and
cholestasis.2,3 Two of the most relevant canalicular
transporters are the bile salt export pump (Abcb11;
also named Bsep), which transports monoanionic bile
salts, and multidrug resistance-associated protein 2
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(Abcc2; also named Mrp2), which transports glutathi-
one and glutathione conjugates, as well as a wide vari-
ety of anionic compounds, such as bilirubin
glucuronides1; bile salts and glutathione are chief
determinants of the so-called bile-salt-dependent and -
independent fractions of bile flow, respectively.4
Different models of experimental cholestasis with
clinical relevance, including estrogen-induced cholesta-
sis, share characteristic alterations in the localization of
canalicular transporters.2,5,6 These works demonstrated
that, in cholestatic conditions, Abcb11 and Abcc2
leave the canalicular membrane, undergoing endocytic
internalization into vesicular compartments. This phe-
nomenon was systematically associated with a failure
in the secretion of their specific substrates, pointing to
a key role of this pathomechanism in the cholestatic
process.
In estrogen-induced cholestasis, and, in particular,
in intrahepatic cholestasis of pregnancy, D-ring metab-
olites of estradiol may be a key factor in its pathogene-
sis. Their levels increase during pregnancy7 and they
induce acute and reversible cholestasis in vivo by
impairing both fractions of bile flow.8 Estradiol 17ß-
D-glucuronide (E17G) is one of these endogenous
D-ring metabolites. The mechanisms involved in
E17G-induced cholestasis seem to be multifactorial.
Transinhibition by E17G of Bsep-mediated canalicular
transport of bile salts9 has been shown to be a causal
factor. In addition, our group showed that
microtubule-independent endocytic internalization of
both Abcb112 and Abcc210 is also a key cholestatic mech-
anism and a feature common to many other cholestatic
conditions, both in experimental animals and humans.11
Intracellular signaling has emerged as a fundamental
element to explain the development of different mod-
els of cholestasis.12 In E17G-induced cholestasis, our
group demonstrated that alteration in canalicular trans-
porters depends on the activation of several signaling
proteins, including “classical” (Ca21-dependent) pro-
tein kinase C (PKC) isoforms (cPKC),13 phosphoinosi-
tide 3-kinase/protein kinase B (PI3K/Akt),14 mitogen-
activated protein kinases (MAPKs) p38 and extracellu-
lar signal-related kinase (ERK)1/2,15 and estrogen
receptor alpha (ER-a).16 Specifically, these previous
works demonstrated that E17G activates, at least, two
signaling branches to induce cholestatic alterations.
The cPKC/ER-a-signaling pathway plays a critical role
in the initial endocytic internalization of canalicular
transporters that leads to cholestasis,13,16 whereas
PI3K/Akt is responsible for maintaining canalicular
transporters internalized, which is independent of
cPKC/ER-a activation.13,14,16
These actions of E17G are similar to the cytosolic
(nongenomic) actions of nonconjugated estradiol
described in different tissues, including liver.17,18 G-
protein-coupled receptor 30 (GPR30) has been impli-
cated in the cytosolic effect of estradiol.19,20 GPR30, a
member of the G-protein-coupled receptor superfam-
ily, is activated by estrogens and acts independently of
ER-a to promote activation of the adenylyl cyclase/
cyclic adenosine monophosphate (AC-cAMP)-depend-
ent protein kinase A (PKA) pathway. Thus, GPR30
would play a critical role in rapid, nongenomic estro-
gen signaling.20 One of the signaling molecules acti-
vated by GPR30 is epidermal growth factor receptor
(EGFR).20 Hence, the aim of this work was to evalu-
ate the potential role of the GPR30-AC/cAMP-PKA
pathway in E17G-induced cholestasis. Finally, we ana-
lyzed whether GPR30 plays a role in one of the previ-
ously characterized cholestatic signaling pathways, that
is, cPKC/ER-a or PI3K/Akt, and the possibility that
EGFR participates downstream of GPR30 in E17G-
induced cholestatic alteration.
Materials and Methods
Additional details on materials and methods are
provided in the Supporting Materials.
Isolated Rat Hepatocyte Couplet Treatments. Iso-
lated rat hepatocyte couplets (IRHCs), obtained as
previously described,21 were exposed to E17G (50
lM) or dimethyl sulfoxide (DMSO; control) for 20
minutes, with or without pretreatment with inhibitors
of the evaluated pathways.
The role of GPR30 in E17G-induced cholestasis
was investigated by preincubating IRHCs with the spe-
cific GPR30 antagonist, G15 (10 nM), for 15 minutes
before exposition to E17G. Then, to evaluate whether
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specific activation of GPR30 was sufficient to repro-
duce E17G-induced cholestasis, cells were incubated
only with the specific GPR30 agonist, G1 (1-1,000
nM), for 20 minutes.
The participation of AC in E17G-induced cholestatic
alterations was examined by pretreating IRHCs with
three different specific inhibitors of AC, SQ22,536 (SQ;
10 lM), MDL12,330 (MDL; 20 lM), or 2030-
dideoxiadenosin (ddA; 1 lM), for 15 minutes. Activa-
tion of AC was evaluated measuring cAMP.22
The likely involvement of PKA in E17G-induced
secretory failure was evaluated by incubating IRHCs
with the PKA inhibitors, KT5720 (KT; 250 nM),
H89 (1lM), or Rp-cAMPS (Rp; 10 lM), for 15
minutes. Activation of PKA was confirmed evaluating
phospho-PKA substrates by western blotting.23
To evaluate the participation of the exchange pro-
tein activated directly by cyclic nucleotide (Epac) path-
way in E17G-induced cholestatic alterations,
experiments were performed under a condition of inhi-
bition of the anticholestatic effects of Epac activa-
tion.23 In these experiments, IRHCs were pretreated
with colchicine (Colch; 1 lM) for 30 minutes and
then exposed to the AC inhibitors, SQ (10 lM),
MDL (20 lM), and ddA (1 lM), for 15 minutes, fol-
lowed by incubation with 50 lM of 8-CPT-20-O-Me-
cAMP (8-CPT) for 15 minutes. Finally, IRHCs were
treated with E17G. Activation of Epac was evaluated
through phosphorylation of MAPK kinase (MEK;
downstream Epac) by western blotting.23
Studies of GPR30 and ER-a/cPKC or PI3K coinhi-
bition were carried out by coadministration of the
antagonist, G15 (10 nM), together with either ER-a
inhibitor ICI 182,780 (ICI; 1 lM), cPKC inhibitor
G€o6976 (G€o; 1 lM), or PI3K inhibitor WM (100
nM) for 15 minutes before exposure to E17G (50
lM) for another 20 minutes.
Participation of EGFR in E17G-induced cholestatic
alterations was evaluated by pretreating IRHCs with
two different specific inhibitors of EGFR, Tyrphostyn
AG1478 (TyrAG; 150 nM) and Cl-7387785 (Cl; 1
lM), for 15 minutes. Additionally, IRHCs were coin-
cubated with TyrAG or Cl together with G15 or WM
for 15 minutes, followed by exposure to E17G for
another 20 minutes.
Assessment of Abcb11 and Abcc2 Secretory Func-
tion and Localization in IRHCs. Functional changes
in Abcb11 and Abcc2 under the treatments described
above were evaluated by assessing the canalicular
vacuolar accumulation (cVA) of cholyl-glycylamido-
fluorescein (CGamF), a fluorescent Abcb11 substrate
(24),24 or glutathione methylfluorescein (GS-MF), a
fluorescent Abcc2 substrate derived from 5-
chloromethylfluorescein diacetate (CMFDA),25 as
described previously.5,23,25
To evaluate the intracellular distribution of Abcb11
and Abcc2, IRHCs were treated with 200 lM of
E17G, a concentration higher than that used in func-
tional experiments, to render transporter retrieval more
evident. After treatments, IRHCs were fixed, permeab-
ilized, and incubated with a polyclonal antibody (Ab)
against mouse Abcb11 or a monoclonal Ab against
human ABCC2, followed by incubation with Cy2-
conjugated donkey anti-rabbit immunoglobulin G
(IgG) or Cy2-conjugated goat anti-mouse IgG, as
described previously.23 To delimit canaliculi, F-actin
was stained by coincubating cells with Alexa Fluor 568
phalloidin (1:100; 1 hour).
Synthesis of Small Interfering RNA. Four 21-
nucleotide (nt) RNA duplexes (small interfering RNA;
siRNA) targeting rat GPR30 messenger RNA were
designed using the WIsiRNA selection program.26 The
control siRNA was designed by scrambling the nts of one
of these specific targets. siRNAs were synthesized using
Ambion’s Silencer siRNA Kit (Ambion, Cambridge, MA).
Assessment of Abcc2 Localization and Secretory
Function in Hepatocytes Cultured in Collagen
Sandwich. Isolated hepatocytes were treated with
siRNA and cultured in collagen sandwich (SCRH) to
allow a polarized configuration, as previously
described.16 After a culture period of 72 hours, SCRHs
were treated with E17G (100 lM; 30 min) or vehicle
(DMSO; control), and the functional status of Abcc2
was evaluated by determination of the pseudocanalicular
accumulation of GS-MF, as previously described.27 In
brief, CMFDA was added to the medium and time-
lapse imaging was done every minute during 8 minutes
with a fluorescence microscope. Between 70 and 100
pseudocanaliculi were selected in each image, and the
average of time fluorescence of GS-MF was measured.
The slope of the line was estimated as a measure of ini-
tial rate of transport (IRT). Intracellular distribution of
Abcc2 in SCRH after treatments was evaluated as previ-
ously described.16
Results
GPR30 Is Necessary, but Not Sufficient, for E17G
to Induce Impairment of Canalicular Secretory
Function. Figure F11A shows that pretreatment with
the GPR30 antagonist, G15, almost completely pre-
vented the effect of E17G on cVA of CGamF and GS-
MF, thus indicating that GPR30 activation is necessary
for E17G to produce its cholestatic effects.
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Fig. 1. Prevention by GPR30 inhibition/knockdown of E17G-induced impairment of canalicular transporters Abcb11 and Abcc2. (A) IRHCs
were preincubated with G15 (10 nM) for 15 minutes and then exposed to E17G (50 lM) for an additional 20-minute period preceding the addi-
tion of CGamF (0.3 lM) or CMFDA (2.5 lM) for 15 minutes. (B) IRHCs were incubated only with G1 (1-1,000 nM). cVA of CGamF and GS-MF
was calculated as the percentage of couplets displaying visible fluorescence in their canalicular vacuoles from a total of at least 200 couplets
per preparation, referred to as control cVA values. cVA control values were 70% 6 2% for CGamF and 77% 6 1% for GS-MF. (C) SCRHs were
transfected with two siRNAs for 48 hours and then exposed to E17G for 30 minutes. The slope of the curve obtained by graphing the average
GS-MF-associated fluorescence of 70-100 pseudocanaliculi versus time was used to estimate the IRT (upper panel) of Abcc2. Representative
confocal images are depicted (lower panels) showing cellular distribution of Abcc2 (green) in SCRH under different treatments. Actin network
(red) and nuclei (blue) are also shown. Under control conditions, Abcc2-associated fluorescence is mainly localized at the canalicular membrane
in the area delimited by the pericanalicular actin network. E17G induced a clear internalization of Abcc2-containing vesicles beyond the limits of
the pericanalicular actin (indicated by arrowheads), a phenomenon significantly prevented by transfection with siRNA1 or siRNA2. None of the
treatments affected the normal distribution of actin, which showed a predominant pericanalicular distribution. aSignificantly different from control
(P < 0.05); bsignificantly different from E17G and control (P < 0.05). Data are expressed as mean 6 standard error of the mean (n 5 3).
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Additionally, concentration-response experiments
with the specific GPR30 agonist, G1, (Fig. 1B) show
that this treatment did not modify cVA of CGamF
and GS-MF, as compared to the control, thus indicat-
ing that the activation of GPR30 is necessary, but not
sufficient, to produce cholestatic effects.
Participation of GPR30 in E17G-induced choles-
tatic alteration was confirmed by evaluation of func-
tion and localization of Abcc2 in SCRH transfected
with siRNA1 and siRNA2. Figure 1C (upper panel)
shows that GPR30 knockdown prevented the func-
tional alteration induced by E17G. The same figure
presents representative confocal images that show that
E17G-induced internalization of Abcc2 was prevented
by GPR30 knockdown, giving additional support to a
role of GPR30 in E17G-induced actions. Cells treated
with scrambled siRNA showed the same delocalization
pattern of Abcc2 as E17G.
AC Inhibition Prevents E17G-Induced Impair-
ment of Canalicular Secretory Function. Figure F22A
shows that treatment with AC inhibitors (SQ, MDL,
or ddA) totally prevented the E17G-induced impair-
ment in Abcb11 and Abcc2 activity, strongly suggest-
ing that AC activation, and therefore cAMP synthesis,
is required by E17G to exert its cholestatic effects.
To confirm the increase in cAMP levels induced by
E17G, we incubated IRHCs with E17G in the pres-
ence of IBMX (phosphodiesterase inhibitor). Figure
2B shows that E17G increases cAMP, this increase
being statistically significant after 10 minutes of incu-
bation. At this time, the increase in cAMP levels
induced by E17G had a magnitude similar to that
Fig. 2. Prevention by AC inhibition of E17G-induced impairment of cVA of CGamF or GS-MF. (A) IRHCs were preincubated with SQ (10 lM),
MDL (20 lM), or ddA (1 lM) for 15 minutes and then exposed to E17G (50 lM) for an additional 20-minute period. Finally, cVA of CGamF
(left panel) and GS-MF (right panel) was calculated as the percentage of couplets displaying visible fluorescence in their canalicular vacuoles
from a total of at least 200 couplets per preparation, referred to as control cVA values. cVA control values were 74% 6 3% for CGamF and
76% 6 3% for GS-MF. aSignificantly different from control (P < 0.05). Data are expressed as mean 6 standard error of the mean (SEM; n 5
3). (B) Left panel shows temporal changes (15 minutes) of cAMP levels of IRHCs exposed to E17G (50 lM). Time 0 min 5 0.8 6 0.3 pmol/
105 IRHC. aSignificantly different from control at time 5 0 min (P < 0.05). Right panel shows cAMP levels of IRHCs pretreated for 15 minutes
with IBMX alone (0.8 mM; control), IBMX1G15 (10 nM), or IBMX1ddA (1 lM) and then exposed to E17G (50 lM), G1 (100 nM), or Forskolin
(5 lM; positive control) for 10 minutes. Control 5 1 6 0.2 pmol/105 IRHC. aSignificantly different from control (P < 0.05); bsignificantly differ-
ent from control and E17G (P < 0.05). Results are expressed as percentage of control as mean 6 SEM (n 5 3).
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attained by the GPR30 agonist, G1. In turn, the
effects of E17G on cAMP levels were completely
blocked when couplets were pretreated with G15 or
ddA. These results indicate that E17G increases cAMP
by GPR30-AC activation. To give additional support
to the role of cAMP, Supporting Fig. 2 shows an
experiment performed to make evident the prochole-
static actions of the second messenger. This experiment
also demonstrates that the presence of the cAMP ana-
log, DB-cAMP, alone is not enough to produce the
cholestatic effects.
PKA, but Not Epac, Is Implicated in E17G-
Induced Impairment of Canalicular Secretory Func-
tion. FigureF3 3A shows that treatment with the three
specific PKA inhibitors (KT, H89, or Rp) totally pre-
vented E17G-induced impairment in Abcb11 and
Abcc2 activities, thus indicating that PKA mediates
E17G-induced cholestasis.
To confirm PKA activation by E17G, kinase activity
was evaluated by western blotting of the phosphoryl-
ated forms of PKA substrates (Fig. 3B). As previously
reported, these immunoblottings show several bands
that would represent phosphorylated PKA sub-
strates.23,28,29 On the basis of their response to the
PKA activator, DB-cAMP, and PKA inhibitors, two
bands of 25 and 110 kDa were analyzed. E17G
increased the phosphorylation of these two PKA sub-
strates, and these increases were blocked by GPR30,
AC, and PKA inhibitors.
Similarly to DB-cAMP, 8-CPT, a specific Epac
agonist, has anticholestatic effects,23 being likely that
their procholestatic effects, if present, would be sur-
passed by its anticholestatic effects. As for DB-cAMP,
the anticholestatic effects of 8-CPT depend on micro-
tubules23 and may be blocked with Colch. FigureF4 4A
shows that in conditions of inhibition of 8-CPT anti-
cholestatic effects, this compound did not revert the
preventive effects of AC inhibitors (MDL and ddA),
thus indicating that Epac activation is not implicated
in E17G-derived, cAMP-dependent cholestatic effects,
at least by a microtubule-independent mechanism. In
addition, western blottings of pMEK, an indicator of
MEK activation (Epac downstream30), revealed that
E17G does not affect MEK activation, whereas 8-
CPT (positive control) significantly increased it (Fig.
4B).
GPR30-AC-PKA Pathway Inhibition Prevents
E17G-Induced Internalization of the Canalicular
Transporters, Abcb11 and Abcc2. FigureF5 5 shows
confocal images of IRHC stained for Abcb11 (Fig.
5A) or Abcc2 (Fig. 5B) under different treatments.
Confocal images show that, in control IRHCs,
Abcb11 and Abcc2 were mainly localized within the
actin pericanalicular ring space. IRHCs treated with
G15, ddA, MDL, H89, or Rp alone exhibited the
same distribution pattern (data not shown). E17G
induced redistribution of both Abcb11 and Abcc2 over
a greater distance from the center of the canalicular
vacuoles. Pretreatment of IRHCs with GPR30, AC,
and PKA inhibitors prevented this delocalization.
These patterns of transporter distribution were con-
firmed by densitometric analysis of confocal images
(Suppoiting Fig. 3). Moreover, densitometric analyses
of actin distribution demonstrated that none of the
treatments produced changes in the canalicular width.
GPR30-AC-PKA Pathway Is Involved in the
Impairment of Biliary Secretory Function Induced
by E17G in Perfused Rat Liver. The bolus adminis-
tration of E17G decreased bile flow to a minimum of
approximately 38% of basal flow within 10 minuets,
and bile flow did not recover throughout the perfusion
period (Fig. F66A). This was accompanied by a decrease
in biliary excretion of the Abcc2 and Abcb11 sub-
strates, S-(2,4-dinitrophenyl) glutathione (DNP-G;
minimum, 45%; Fig. 6B) and sodium taurocholate
(TC; minimum, 35%; Fig. 6C), respectively. Both
transport activities recovered to approximately 70% of
basal values from 15 minutes after E17G administra-
tion onward. The cumulative excretion of DNP-G
decreased to 61% 6 3%, whereas TC cumulative
excretion was 59% 6 2% of control values after
E17G administration. Inhibition of GPR30-AC-PKA
at three different levels prevented, in a similar manner,
the initial drop in bile flow (minimum of approxi-
mately 78%) and completely prevented bile flow alter-
ations induced by E17G from 15 minutes onward.
G15, ddA, or H89 preadministration also preserved
the biliary excretion of Abcc2 and Abcb11 substrates
in E17G-treated rats, where DNP-G excretion reached
a minimum of approximately 80% and that of TC
reached a minimum of approximately 76%. Then,
excretion of both substrates in rats treated with
GPR30-AC-PKA inhibitors plus E17G increased and
overtook substrate excretion in control rats 15 minuets
after E17G injection, being similar to controls after.
As a result, the cumulative excretion of DNP-SG
(98% 6 2%) and TC (87% 6 5% of control) in
G15/ddA/H89 plus E17G rats did not differ from
that of control rats.
Confocal images show that in E17G-treated livers,
both Abcb11 (Fig. F77A) and Abcc2 (Fig. 7B) were
detected in intracellular structures, consistent with
their endocytic retrieval from the canalicular mem-
brane. In livers perfused with G15/ddA/H89 plus
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E17G, the distribution of both Abcb11 and Abcc2
was almost identical to that in control livers and this
was confirmed by densitometric analysis (Supporting
Fig. 4). Neither E17G nor GPR30-AC-PKA pathway
inhibitors altered the canalicular width estimated by
the two densitometric peaks of occludin.
Fig. 3. Prevention by PKA inhibition of E17G-induced impairment of cVA of CGamF or GS-MF and estimation of PKA activation by E17G. (A)
IRHCs were preincubated with KT (0.25 lM), H89 (1 lM), and Rp (10 lM) for 15 minutes and then exposed to E17G (50 lM) for an additional
20-minute period. Finally, cVA of CGamF (upper panel) and GS-MF (lower panel) was calculated as the percentage of couplets displaying visible
fluorescence in their canalicular vacuoles from a total of at least 200 couplets per preparation, referred to as control cVA values. cVA control val-
ues were 74% 6 3% for CGamF and 76% 6 3% for GS-MF. aSignificantly different from control (P < 0.05); bsignificantly different from control
and E17G (P < 0.05). Data are expressed as mean 6 standard error of the mean (SEM; n 5 3). (B) Isolated rat hepatocytes were incubated
with DB-cAMP (10 lM; positive control) in the presence or absence of PKA inhibitors (KT [0.25 lM], H89 [1 lM], or Rp [10 lM]), G1 (100
nM), or E17G (50 lM) in presence or absence of GPR30-AC-PKA inhibitors (G15 [10 nM], MDL [20 lM], ddA [1 lM], KT [0.25 lM], H89 [1
lM], or Rp [10 lM]). PKA activity was determined by western blotting, using an Ab against phosphorylated PKA substrates. Two bands of 25
and 110 kDa were analyzed based on their response to DB-cAMP and PKA inhibitors. Two exposure times were necessary to reveal these bands:
a short exposure for the 25-kDa band and a long exposure for the 110-kDa band. Differences in sample loading were corrected by the densito-
metric signal of the corresponding actin band. The ratio of each phosphorylated substrate/actin band density was compared to that of control
bands (100%). Data are expressed as mean 6 SEM (n 5 3). aSignificantly different from control (P < 0.05); bsignificantly different from the
agonist alone (P < 0.05).
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Interaction Between GPR30-AC-PKA and Other
Signaling Pathways Implicated in E17G-Induced
Cholestatic Alteration. The preventive effects of G15
and ICI or G€o on decreases in cVA of CGamF and GS-
MF induced by E17G were additive (Fig.F8 8A), suggesting
that GPR30 and cPKC/ER-a were acting independently.
This was confirmed in cholestatic alterations induced by
E17G because neither ICI affects the increase of cAMP
produced by E17G (Supporting Fig. 5A, left panel) nor
does treatment with G15, ddA, or H89 (Supporting Fig.
5A, right panel) affect the activation of ER-a measured
by western blotting.
Contrarily, no additive effect was observed with G15 and
WM (Fig. 8A), suggesting that GPR30 and PI3K share a
common pathway. The sequential activation of GPR30 and
PI3K was confirmed by measuring the activation of Akt, a
kinase downstream PI3K. Figure 8B shows that pretreat-
ment with G15 prevented the activation of Akt produced
by E17G. Moreover, PI3K inhibition did not affect the
increase in cAMP produced by E17G (Supporting Fig. 5A,
left panel). However, ddA and H89 did not affect Akt acti-
vation. These findings indicate that PI3K/Akt activation is
mediated by GPR30 independently of AC or PKA.
Finally, we analyzed the participation of EGFR in
E17G-induced cholestasis by pretreatment of IRHCs
with two specific inhibitors of EGFR (TyrAG and Cl).
Both inhibitors partially prevented the decrease in cVA
of CGamF and GS-MF induced by E17G, indicating
that EGFR participates in the E17G cholestasis. We
found additive-preventive effects when cells were coin-
cubated with G15 or WM, suggesting that EGFR par-
ticipates in E17G-induced cholestasic alteration by a
mechanism independent of GPR30/PI3K. This inde-
pendent action was confirmed because neither EGFR
inhibitors affected the increase in cAMP levels (Sup-
porting Fig. 5A, left panel) or Akt activation induced
by E17G (Fig. 8C) nor did G15, ddA, H89, and WM
affect the activation of EGFR produced by E17G
(Supporting Fig. 5B). These data show that EGFR is
activated, and participates, in E17G-induced cholesta-
sis through a mechanism independent from GPR30,
AC, PKA, and PI3K.
Fig. 4. Epac is not involved in E17G-induced alteration of canalicular transporters. (A) IRHCs were pretreated with Colch (1 lM) for 30
minutes and with MDL (20 lM), ddA (1 lM) for 15 minutes, followed by treatment with 8-CPT (50 lM) for 15 minutes and incubation with
E17G (50 lM) for 20 minutes. Finally, IRHCs were exposed to CGamF (0.3 lM; left panel) and CMFDA (2.5 lM; right panel) for 15 minutes,
and cVA of these fluorescent substrates was calculated as the percentage of couplets displaying visible fluorescence in their canalicular vacuoles
from a total of at least 200 couplets per preparation, referred to as control cVA values. Control cVA values were 74% 6 3% for CGamF and
75% 6 1% for GS-MF. aSignificantly different from control (P < 0.05); bsignificantly different from E17G and control (P < 0.05); csignificantly
different from E17G18-CPT (P < 0.05); dsignificantly different from Colch1E17G (P < 0.05). Data are expressed as mean 6 standard error of
the mean (SEM; n 5 3). (B) Isolated rat hepatocytes were incubated with E17G (50 lM) and 8-CPT (50 lM; positive control). MEK (kinase
downstream of EPAC) activity was determined by immunoblottings, using an Ab against phosphorylated MEK1/2. A band at 45 kDa was
detected. Differences in sample loading were corrected by the densitometric signal of the corresponding actin band. The ratio of each pMEK/
actin band density was compared with the ratio of control bands (100%). Data are expressed as mean 6 SEM (n 5 3). aSignificantly different
from control (P < 0.05).
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Discussion
Intracellular signaling cascades are key factors in the
onset of cholestatic phenomena.12 In E17G-induced
cholestasis, several signaling molecules have been
implicated, such as ER-a, cPKC, and PI3K.13-16 In
the present study, we demonstrate the participation of
the cAMP-PKA pathway in estrogen cholestasis. The
association of this pathway with E17G effects was
revealed by the strong anticholestatic actions associated






Fig. 5. Prevention of E17G
(200 lM)-induced retrieval of
Abcb11/Abcc2 by inhibition of
the GPR30-AC-PKA pathway.
Representative confocal images
show cellular distribution of
Abcb11 (A) or Abcc2 (B), actin,
and merged images in IRHCs
under different treatments. Under
control conditions, Abcb11/
Abcc2-associated fluorescence
is mainly localized at the cana-
licular membrane in the area
delimited by the pericanalicular
actin ring. E17G induced a clear
internalization of Abcb11/Abcc2-
containing vesicles beyond the
limits of the pericanalicular actin
ring, a phenomenon significantly
prevented by treatment of IRHC
with G15 (10 nM), MDL (20
lM) ddA (1 lM), H89 (1 lM),
or Rp (10 lM). None of the
treatments affected the normal
distribution of actin, which
showed a predominant pericana-
licular distribution.
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Generally, cAMP synthesis starts with stimulation of
a G-protein-coupled receptor and, consequently, with
the activation of an adenylyl-cyclase.31 GPR30 is a
receptor that mediates several cytosolic effects of non-
conjugated estradiol in several tissues, including the
liver.19 Given that nonconjugated estradiol and E17G
activate similar pathways,13-16,18,31 we analyzed
whether E17G is able to mediate its cholestatic effect
by GPR30 activation. We observed that blocking
GPR30, by inhibition or knockdown, prevented,
almost completely, the cholestatic effects induced by
E17G. We also proved that E17G-induced increase in
cAMP levels or PKA activation are completely blocked
in the presence of G15, an antagonist of GPR30. This
finding points to a sequential activation of the
GPR30-AC-PKA pathway. In line with this, Hsieh
et al.32 showed PKA activation by nonconjugated
estradiol by GPR30 modulation. Furthermore, we
observed that another potential effector pathway of
cAMP, that of the Epac protein, is not involved in
E17G-induced cholestasis.
It is worth noting that specific activation of GPR30
using the agonist G1 or direct administration of DB-
cAMP, under a condition of inhibition of its antichole-
static effects, did not reproduce the cholestatic effect
induced by E17G. Potential explanations for these
findings could be that the action of E17G on GPR30
evokes different downstream signaling pathways, as
compared to activation by the specific agonist, G1
(e.g., mediated by post-translational modifications of
GPR30 by E17G) or, alternatively, that E17G needs
to modulate additional signaling molecules to induce
cholestasis. A potential candidate associated with this
fact is ER-a. Indeed, our group recently demonstrated
a critical role of the ER-a/cPKC-signaling pathway in
the initial endocytic internalization of canalicular
transporters induced by E17G.13,16 In this work, we
give evidences indicating that GPR30 and cPKC/ER-a
act in different pathways, so we can speculate that
E17G activates GPR30 and simultaneously modulates
ER-a activity, these two events being necessary and
independent to produce cholestasis.
Recently, our group also showed that E17G activates
a pathway that involves PI3K/Akt, allegedly responsi-
ble for maintaining internalized canalicular
Fig. 6.
Fig. 6. Inhibition of the GPR30-AC-PKA pathway protects against
E17G-induced impairment of bile flow and biliary secretion of DNP-G
and TC in PRL. Graphics show temporal changes in bile flow (A) and
in the biliary excretion rate of both total DNP-G (B) and TC (C)
throughout the perfusion period. PRLs were treated with a bolus of
E17G (3 lmol/liver) or its vehicle (DMSO/bovine serum albumin 10%
in saline; control) in the presence or absence of G15 (10 nM), ddA (1
lM), or H89 (1 lM). aControl significantly different from E17G;
bE17G1G15 significantly different from control; cE17G1ddA signifi-
cantly different from control; dE17G1H89 significantly different from
control; eE17G1G15 significantly different from E17G; fE17G1ddA
significantly different from E17G; gE17G1H89 significantly different
from E17G (P < 0.05; n 5 3 animals per group).
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transporters, which is independent of cPKC/ER activa-
tion.13,16 These works demonstrated that inhibition of
either of these two signaling pathways had a partial
preventive effect. The results obtained in the present
study also show, both in IRHC and perfused rat liver






Fig. 7. Inhibition of the GPR30-AC-PKA pathway prevents E17G-induced retrieval of Abcb11 (A) and Abcc2 (B) in PBL. Representative confo-
cal images of immunostained liver samples show distribution of Abcb11 (A) or Abcc2 (B) and occludin. In control livers, both Abcb11 and
Abcc2 were mainly confined to the canalicular space delineated by the tight junction-associated protein, occludin. After E17G (3 lmol/liver),
some canaliculi show intracellular fluorescence associated with Abcb11 or Abcc2 at a greater distance from the canalicular membrane, consist-
ent with their endocytic retrieval. G15 (10 nM), ddA (1 lM), or H89 (1 lM), 15 minutes before E17G addition, prevented the internalization of
canalicular transporters, as illustrated by a control-like pattern of Abcb11 and Abcc2 distribution. G15, ddA, or H89 themselves did not induce
any changes in transporter localization.
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Fig. 8. Possible mechanisms by which GPR30-AC-PKA participates in E17G-induced canalicular secretory failure. (A) IRHCs were treated with
G15 (10 nM) together with ICI (1 lM), G€o (1 lM), or WM (100 nM) for 15 minutes, followed by treatment with E17G (50 lM) for 20 minutes.
Finally, IRHCs were exposed to CGamF (0.3 lM; upper panel) and CMFDA (2.5 lM; lower panel) for 15 minutes, and cVA of these fluorescent
substrates was calculated as the percentage of couplets displaying visible fluorescence in their canalicular vacuoles from a total of at least 200
couplets per preparation, referred to as control cVA values. Control cVA values were 70% 6 3% for CGamF and 71% 6 1% for GS-MF. aSignifi-
cantly different from control (P < 0.05); bsignificantly different from E17G and control (P < 0.05); csignificantly different from E17G1G15,
E17G1ICI, E17G1G€o, and E17G1WM (P < 0.05). Data are expressed as mean 6 standard error of the mean (SEM; n 5 3). (B) IRHCs were
treated with TyrAG (150 nM) or Cl (1 lM) together with G15 (10 nM) or WM (100 nM) for 15 minutes, followed by treatment with E17G (50
lM) for 20 minutes. Finally, IRHCs were exposed to CGamF (0.3 lM; upper panel) and CMFDA (2.5 lM; lower panel) for 15 minutes and cVA
of these fluorescent substrates was calculated. Control cVA values were 69% 6 1% for CGamF and 68% 6 3% for GS-MF. aSignificantly different
from control (P < 0.05); bsignificantly different from E17G and control (P < 0.05); csignificantly different from E17G1TyrAG, E17G1Cl,
E17G1G15, and E17G1WM (P < 0.05). Data are expressed as mean 6 SEM (n 5 3). (C) Isolated rat hepatocytes were preincubated with
G15 (10 nM), ddA (1 lM), or H89 (1 lM), WM (100 nM), TyrAG (150 nM), and Cl (1 lM) for 15 minutes, followed by incubation with E17G
(200 lM) for 20 minutes. PI3K activation was determined using an Ab against phosphorylated Akt (a PI3K effector). A band at 56 kDa was
detected. The ratio of pAkt/total Akt density for each treatment was compared to the ratio of control bands (100%). Data are expressed as
mean 6 SEM (n 5 3). aSignificantly different from control; bsignificantly different from E17G (P < 0.05).
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pathway at any of its three levels produces a strong
preventive effect on E17G-induced impairment of
transporter activity and localization. These results allow
us to speculate that this signaling pathway would play
a pivotal role in initiating E17G-induced cholestasis.
Studies of the interdependence of the PI3K/Akt and
GPR30 pathways indicate that E17G activates PI3K/
Akt through GPR30, but independently of AC or
PKA. These findings allow us to speculate that GPR30
can activate at least two signaling branches: one
dependent and the other independent of AC/PKA.
The pathway that relies on cAMP and PKA activa-
tion could play a role in the endocytosis of canalicular
transporters independent from the ER-a/cPKC path-
way. In line with this, the dual anchoring protein, D-
AKAP2/AKAP10, a binding partner for both the RI
and RII subunits of PKA, interacts with Rab11 and
promotes accumulation of recycling transferrin in
Rab11-positive endosomes.33 Because internalized
Abcb11 and Abcc2 colocalize with Rab11a,23 it is pos-
sible to speculate on a role for PKA/AKAP in the recy-
cling of endosomes containing Rab11a and Abcb11 or
Abcc2.
Another possible target of the cAMP/PKA pathway
is the regulation of the calcium/calmodulin pathway.
We have recently provided evidence that L-type cal-
cium channels, calmodulin, and a direct effector
(CamKII) participate in E17G-induced cholestasic
alterations.34 In relation with this, PKA can regulate
L-type calcium channels35 and phosphorylate ryano-
dine receptor, thus modulating intracellular calcium
levels.36 Moreover, PKA can modulate endocytosis in
neurons by calmodulin activity modulation.37 Hence,
it is possible to hypothesize that activation of PKA by
E17G triggers calcium/calmodulin-dependent signaling
that leads to endocytosis of Abcb11 and Abcc2.
The other signaling branch triggered by GPR30
could activate the PI3K/Akt pathway and maintain
internalized Abcb11 and Abcc2. Consistent with these
results, Wang et al.20 propose that estrogen regulates a
plethora of biological processes through the
membrane-initiated signaling of the GPR30 pathway,
in which PI3K would act downstream of this receptor
by a mechanism independent of AC/PKA. In this
work, transactivation of EGFR by GPR30 was also
described as a common mechanism that finally acti-
vates different effectors (including PI3K). So, we ana-
lyzed the participation of EGFR in E17G-induced
cholestasis. We observed both activation of EGFR by
E17G and prevention of cholestasis by EGFR inhibi-
tors. However, neither was EGFR activation blocked
by G15 nor did experiments with coinhibition of
GPR30 or PI3K and EGFR show nonadditive effects.
These indicate that EGFR participates in E17G-
induced cholestasis by a mechanism independent of
GPR30. Song et al.38 described another mechanism by
which EGFR participates in extranuclear effects of
nonconjugated estradiol. The mechanism proposed is
that classical ER-a transactivates EGFR and this ini-
tiates nongenomic signaling pathways. Our results and
this fact allow us to speculate that in E17G-induced
cholestasis, EGFR is probably activated by ER-a, inde-
pendently of GPR30.
Finally, this work represents the first report where
cAMP behaves as a procholestatic signaling molecule
promoting endocytic internalization of canalicular
transporters. In contrast to these results, numerous
studies have previously demonstrated that cAMP is an
anticholestatic signaling molecule.23,39 These opposing
effects of cAMP can be explained by the compartmen-
talization of this second messenger, because within the
cell, adenylyl-cyclases, phosphodiesterases, and pathway
effectors are closely associated. Therefore, cAMP gen-
eration and degradation is compartmentalized, leading
to the existence of localized pools of the messenger. In
accord with this fact, our group recently showed that
cAMP derived from hormones, such as glucagon and
adrenaline, have beneficial effects by the activation of
different intracellular mechanisms.11,23 Further sup-
porting this, experiments performed in cellular frac-
tions (cytosolic, mitochondrial, and plasmatic
membrane fractions) showed that the pattern of phos-
phorylation of PKA substrates differs between gluca-
gon and E17G (Supporting Fig. 6). In cytosolic
fractions, we found a band of 80 kDa that is phospho-
rylated mainly by E17G, but not by glucagon, and
another of 110 kDa that is phosphorylated by both.
Instead, in mitochondrial fractions, a band at 37 kDa
is strongly phosphorylated by glucagon and, to a lesser
extent, by E17G, and a band of 25 kDA is phospho-
rylated by both. In plasmatic membrane fraction, we
found a possible substrate at 50 kDA that is phospho-
rylated in a similar manner by Glu and E17G.
In summary, activation of GPR30-AC-PKA is a key
factor in the alteration of canalicular transporters
induced by E17G. The interaction of E17G with
GPR30 would be the first event in the cascade of sig-
naling activation. This hypothesis is supported by the
fact that GPR30 or AC inhibition completely blocked
E17G insult, a feature that differs with what was pre-
viously observed in experiments using PKC and PI3K
inhibitors, whose protection was only partial. Never-
theless, GPR30-AC-PKA activation is necessary for
E17G-induced cholestasis, but is not enough, because
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the agonists of this pathway, when used alone, were
not able to trigger the cholestatic process.
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